Abstract:Zhisheng Huang, 1, 2 Zuowang Cheng, 3 Xia Deng, 4 Ying Yang, 5 Na Sun, 5 Peibin Hou, 5 Ruyue Fan, 5 Shuai Liu 6, 7 1 Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China; 2 Department of Pulmonary and Critical Care Medicine, National Regional Center for Respiratory Medicine, Jiangxi Hospital of China-Japan Friendship Hospital, Nanchang, Jiangxi, People's Republic of China; 3 Department of Clinical Laboratory, Zhangqiu District People's Hospital Affiliated to Jining Medical University, Jinan, Shandong, People's Republic of China; 4 School of Public Health, Shandong Second Medical University, Weifang, Shandong, People's Republic of China; 5 Shandong Center for Disease Control and Prevention, Jinan, Shandong, People's Republic of China; 6 Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China; 7 Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, Shandong, People's Republic of China Correspondence: Shuai Liu; Ruyue Fan, Email ; Background: Coronavirus disease 2019 (COVID-19) is a respiratory infectious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The objective of this study is to identify reliable and accurate biomarkers for the early stratification of disease severity, a crucial aspect that is currently lacking for the impending phases of the next COVID-19 pandemic. Methods: In this study, we identified important module and hub genes related to clinical severe COVID-19 using differentially expressed genes (DEGs) screening combing weighted gene co-expression network analysis (WGCNA) in dataset GSE213313. We further screened and confirmed these hub genes in another two new independent datasets (GSE172114 and GSE157103). In order to evaluate these key genes' stability and robustness for diagnosing or predicting the progression of illness, we used RT-PCR validation of selected genes in blood samples obtained from hospitalized COVID-19 patients. Results: A total of 968 and 52 DEGs were identified between COVID-19 patients and normal people, critical and non-critical patients, respectively. Then, using WGCNA, 10 modules were constructed. Among them, the blue module positively associated with clinic disease severity of COVID-19. From overlapped section between DEGs and blue module, 12 intersected common differential genes were obtained. Subsequently, these hub genes were validated in another two new independent datasets as well and 9 genes that overlapped showed a highly correlation with disease severity. Finally, the mRNA expression levels of these hub genes were tested in blood samples from COVID-19 patients. In severe cases, there was increased expression of MCEMP1, ANXA3, CD177 , and SCN9A . In particular, MCEMP1 increased with disease severity, which suggested an unfavorable development and a frustrating prognosis. Conclusion: Using comprehensive bioinformatical analysis and the validation of clinical samples, we identified four major candidate genes, MCEMP1, ANXA3, CD177 , and SCN9A , which are essential for diagnosis or development of COVID-19. Keywords: COVID-19, differentially expressed genes, WGCNA, hub genes, neutrophil Over the past four years, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a worldwide health concern. As of 8 November 2023, there have been 771 million reported cases in 188 countries and territories, resulting in over 6.97 million deaths. 1 The disease can manifest in various degrees of severity, ranging from mild to critical. Moreover, emerging evidence suggests that individuals infected with SARS-CoV-2 can be asymptomatic carriers, contributing to the silent spread of the virus. 2,3 Despite extensive investigation, the underlying question of why there is such a marked difference in the disease progression among infected individuals remains unresolved. Current studies highlight that the illness severity and progression are largely determined by the dysregulated host inflammatory response. 4–6 When a virus penetrates a cell, it may activate both innate and adaptive host immune responses, which are critical components of viral defense. 7,8 The exaggerated or dysregulated inflammatory responses and an imbalanced adaptive immunity may account for severe tissue destruction. 9 The preexisting immunity on the response to vir -Abstract Truncated-

COVID-19 of differing severity: from bulk to single-cell expression data analysis

Potential Core Genes Associated with COVID-19 Identified Via Weighted Gene Co-Expression Network Analysis.

Integrated Bioinformatics Exploration and Preliminary Clinical Verification for the Identification of Crucial Biomarkers in Severe Cases of COVID-19

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Single-cell transcriptomes of peripheral blood cells indicate and elucidate severity of COVID-19

Tracing the cell-type-specific modules of immune responses during COVID-19 progression using scDisProcema

Identification of COVID-19 severity biomarkers based on feature selection on single-cell RNA-Seq data of CD8+ T cells.

Identification of Gene Markers Associated with COVID-19 Severity and Recovery in Different Immune Cell Subtypes.

Comparative Analysis of Long Non-Coding RNA Expression and Immune Response in Mild and Severe COVID-19

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods

Identification of Novel Drug Targets for the Risk and Prognosis of COVID-19

Whole-Transcriptome RNA Sequencing Reveals Significant Differentially Expressed mRNAs, miRNAs, and lncRNAs and Related Regulating Biological Pathways in the Peripheral Blood of COVID-19 Patients

The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+monocytes and memory CD8+T cells involved in severe COVID-19

Transcriptional Start Site Coverage Analysis in Plasma Cell-Free DNA Reveals Disease Severity and Tissue Specificity of COVID-19 Patients

Single-cell RNA-seq and V(D)J profiling of immune cells in COVID-19 patients

Single-cell analysis reveals cell communication triggered by macrophages associated with the reduction and exhaustion of CD8+ T cells in COVID-19

COVID-19 Severity is Associated with Immunopathology and Multi-Organ Damage

Single-cell landscape of immunological responses in patients with COVID-19

Integration of human organoids single-cell transcriptomic profiles and human genetics repurposes critical cell type-specific drug targets for severe COVID-19